E.g., 06/26/2019
E.g., 06/26/2019
Title Category Credit Event date Price
Annual Review Course Webcast (2018) $1,400.00 Specifically designed for anyone unable to get away from the office to attend the Live Course, the Webcast option delivers the same great content. Purchase of the Webcast features simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.
AUA Annual Meeting Highlights (2018): Immunotherapy in GU Cancer
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Non-Physician Participation
$0.00 An AUA survey indicated that urologists see an average of 17 patients a month with bladder cancer. While 84% of respondents felt very knowledgeable about the surgical treatment options, only 44% of them felt very knowledgeable about chemotherapy and immunotherapy options. When asked about increasing their knowledge in the area of bladder cancer 75.4% stated it was necessary to extremely necessary.
AUA2017 OnDemand Course Pass (2017) $299.00 Access some of the latest science from AUA2017 through the On-Demand Course Pass! The On-Demand Course Pass provides access to Webcasts of more than 90 instructional courses presented at AUA2017. Course topics span the spectrum of urologic medicine.
AUA2018 Abstracts and Posters (2018) $0.00 Member only benefit! This is a collection of abstracts presented at the AUA2018.This product does not provide CME.To access abstracts and posters, click REGISTER/TAKE COURSE tab. Then click ENROLL at the bottom of the page.
AUA2018 San Francisco Virtual Meeting (2018) $699.00 NEW for 2018: AUA2018 Virtual Meeting - Members Save $100!Access the latest science from the 2018 AUA Annual Meeting with the AUA2018 VIRTUAL MEETING.The Virtual Meeting provides online access to hundreds of scientific presentations from AUA2018, including:
Breaking Down the Barriers: Incorporating New IO Therapies Podcast Series - Biomarkers (2018)
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
$0.00 To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals.The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.
Breaking Down the Barriers: Incorporating New IO Therapies Podcast Series - How to Properly Administer IO Therapies in an Infusion Suite (2018)
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
$0.00 To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals.The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.
Breaking Down the Barriers: Incorporating New IO Therapies Podcast Series - Managing Patient Side Effects (2018)
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
$0.00 To improve clinicians’ understanding of current immunotherapeutic agents for the treatment of genitourinary (GU) cancer and to increase their ability to improve patient outcomes and the management of adverse events, the AUA is producing a series of online activities for clinicians and other healthcare professionals.The 2018 series is comprised of a variety of activities, including four live webinars, webcasts and podcasts plus three podcast addressing the barriers to immunotherapy treatment of GU cancer. All activities are complimentary.
Chemotherapy & Immunotherapy Options for Genitourinary Malignancies: A Primer for the Advanced Practice Provider Webcast 005IC (2018)
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$0.00 Review of current chemotherapy and immunotherapy regimens for genitourinary malignancies, including bladder, renal, and prostate cancers. Indications, outcomes, and toxicities will be discussed as well as clinical trial concepts. Survivorship issues will also be a focus of the session, which will include short, direct didactic lectures as well as a panel discussion with an interactive component. Standard of care chemotherapy regimens (eg MVAC for urothelial carcinoma) as well as newer immunotherapy options (eg checkpoint inhibition for renal cell carcinoma) will be included.
Complex Patient Cases in Bladder Cancer Webcast (2017)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 The AUA developed the Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer initiative to include multiple educational interventions to improve the urologist, medical oncologist, and other healthcare provider's ability to care for patients with bladder cancer. These activities are designed to increase the clinician's competence in the application of new and emerging treatment options, including the sequencing and associated side effects of those options.
CPS Muscle Invasive Bladder Cancer (2017)
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$0.00 AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Problem Solving (CPS) Protocols guideline-based Case Scenarios were designed to help maximize the impact of the guidelines. The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of muscle invasive bladder cancer (MIBC).
CPS Non-Muscle Invasive Bladder Cancer (2016)
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
$0.00 Member only benefit! AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Problem Solving (CPS) Protocols guideline-based Case Scenarios were designed to help maximize the impact of the guidelines. This guideline provides a risk-stratified clinical framework for the management of NMIBC.
Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer (2017)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 The AUA developed the Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer initiative to include multiple educational interventions to improve the urologist, medical oncologist, and other healthcare provider's ability to care for patients with bladder cancer. These activities are designed to increase the clinician's competence in the application of new and emerging treatment options, including the sequencing and associated side effects of those options.
Fundamentals in Urology Webcast (2018) $805.00 Specifically designed for anyone unable to get away from the office to attend the Live Course - the Webcast option delivers the same great content. Purchase of the Webcast features simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials. 
Highlights in the Medical Management of Urothelial Carcinoma: Advanced and Metastatic Urothelial Carcinoma (2019)
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
$0.00 The Live from AUA2019: Highlights in the Medical Management of Urothelial Carcinoma is compromised of two panel discussions filmed at the 2019 AUA Annual Meeting in Chicago focused on optimizing the treatment of urothelial carcinoma.  The panel discussions will present the latest developments in the:1) Management of Non-Muscle Invasive Urothelial Carcinoma (see below for a link to the activity)2) Management of Advanced and Metastatic Urothelial Carcinoma

Pages